Ruben A. Garcia

CIK: 0002013617

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

FBLG

FibroBiologics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

FBLG
FibroBiologics, Inc.
May 4, 2026
Award(A)
Stock Option (Right to Buy)
Direct
61.6K shares-
FBLG
FibroBiologics, Inc.
Feb 27, 2026
Purchase(P)
Direct
40K shares at avg. $0.33$13K
FBLG
FibroBiologics, Inc.
Dec 11, 2025
Purchase(P)
Direct
140K shares at avg. $0.34$48K
FBLG
FibroBiologics, Inc.
Mar 26, 2025
Award(A)
Stock Option (Right to Buy)
Direct
189K shares-
FBLG
FibroBiologics, Inc.
Dec 27, 2024
Award(A)
Stock Option (Right to Buy)
Direct
176.2K shares-

		Type	Shares	Price		Ownership
May 4, 2026	FBLG FibroBiologics, Inc.	Award(A) Stock Option (Right to Buy)	61,607	-	-	Direct
Feb 27, 2026	FBLG FibroBiologics, Inc.	Purchase(P)	40,000	$0.33	$13,056	Direct
Dec 11, 2025	FBLG FibroBiologics, Inc.	Purchase(P)	140,000	$0.34	$47,600	Direct
Mar 26, 2025	FBLG FibroBiologics, Inc.	Award(A) Stock Option (Right to Buy)	189,000	-	-	Direct
Dec 27, 2024	FBLG FibroBiologics, Inc.	Award(A) Stock Option (Right to Buy)	176,200	-	-	Direct

1-5 of 5 transactions

About GARCIA RUBEN A

GARCIA RUBEN A (SEC CIK 0002013617) files insider reports with the SEC as General Counsel of FibroBiologics, Inc. (FBLG).

Signal8 holds 5 ownership filings by GARCIA RUBEN A, all Form 4s, filed between Dec 30, 2024 and May 4, 2026. Those filings report 5 transactions, from Dec 27, 2024 to May 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on GARCIA RUBEN A's filings is in HOUSTON,, TX.

Recent filings by GARCIA RUBEN A

May 4, 2026: Grant or award of FBLG derivative securities (Form 4, code A).
Feb 27, 2026: Open-market purchase of FBLG shares (Form 4, code P).
Dec 11, 2025: Open-market purchase of FBLG shares (Form 4, code P).
Mar 26, 2025: Grant or award of FBLG derivative securities (Form 4, code A).
Dec 27, 2024: Grant or award of FBLG derivative securities (Form 4, code A).

Other insiders filing for FibroBiologics, Inc. (FBLG)

Khoja Hamid, Chief Scientific Officer
Steinberg Leigh, Director
Rubins Kathleen Hallisey, Director
Hoffman Robert E., Director
Cilento Richard C. Jr., Director
Link Matthew, Director

How to read Form 4 transaction codes